section name header

Pronunciation

em-pa-gli-FLOE-zin/lin-a-GLIP-tin

Classifications

Therapeutic Classification: antidiabetics

Pharmacologic Classification: sodium-glucose co-transporter 2 (SGLT2) inhibitors, dipeptidyl peptidase-4 dpp-4 inhibitors

Indications

BEERS REMS


Action

  • Empagliflozin: Inhibits proximal renal tubular sodium-glucose cotransporter 2 (SGLT2), which determines reabsorption of glucose from the tubular lumen. Inhibits reabsorption of glucose, lowers renal threshold for glucose, and increases excretion of glucose in urine.
  • Linagliptin: Inhibits the enzyme dipeptidyl peptidase-4 (DPP-4), which slows the inactivation of incretin hormones, resulting in increased levels of active incretin hormones. These hormones are released by the intestine throughout the day and are involved in regulation of glucose. Increased/prolonged incretin levels increase insulin release and decrease glucagon levels.
Therapeutic effects:
  • Improved glycemic control.
  • Reduced death due to cardiovascular causes.

Pharmacokinetics

Empagliflozin

Absorption: Well absorbed following oral administration.

Distribution: Enters red blood cells; remainder of distribution unknown.

Metabolism/Excretion: Minimally metabolized; excreted in feces (41.2% mostly as unchanged drug) and urine (54.4% half as unchanged drug, half as metabolites).

Half-Life: 12.4 hr.

Linagliptin

Absorption: 30% absorbed following oral administration.

Distribution: Extensively distributed to tissues.

Metabolism/Excretion: Approximately 90% excreted unchanged in urine; minimally metabolized.

Half-Life: >100 hr (due to saturable binding to DPP-4).

Time/Action Profile

( in A1c)
ROUTEONSETPEAKDURATION
empagliflozin (PO)within 6 wk12 wkunknown
linagliptin (PO)unknown1.5 hr24 hr



Plasma concentrations.



Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Empagliflozin

CV: hypotension, volume depletion

Endo: hypoglycemia (with other medications)

F and E: hyperphosphatemia, KETOACIDOSIS

GU: urination, acute kidney injury, genital mycotic infections, NECROTIZING FASCIITIS OF PERINEUM (FOURNIER'S GANGRENE), renal impairment, urinary tract infections (including pyelonephritis), UROSEPSIS

Metab: hyperlipidemia

MS: lower limb amputation

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Linagliptin

CV: HF

Derm: bullous pemphigoid, localized exfoliation, urticaria

GI: PANCREATITIS

Metab: hypoglycemia, hypertriglyceridemia

MS: RHABDOMYOLYSIS

Resp: bronchial hyperreactivity

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions

Drug-drug:

Route/Dosage

Availability

(Generic available)

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Glyxambi